We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

246 hedge funds and large institutions have $2.32B invested in Syndax Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 99 increasing their positions, 68 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more call options, than puts

Call options by funds: $15.2M | Put options by funds: $8.14M

80% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 25

46% more repeat investments, than reductions

Existing positions increased: 99 | Existing positions reduced: 68

11% more capital invested

Capital invested by funds: $2.1B → $2.32B (+$222M)

7% more funds holding

Funds holding: 229 → 246 (+17)

2.28% less ownership

Funds ownership: 114.94% → 112.66% (-2.3%)

9% less funds holding in top 10

Funds holding in top 10: 11 → 10 (-1)

Holders
246
Holders Change
+17
Holders Change %
+7.42%
% of All Funds
3.03%
Holding in Top 10
10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-9.09%
% of All Funds
0.12%
New
45
Increased
99
Reduced
68
Closed
25
Calls
$15.2M
Puts
$8.14M
Net Calls
+$7.04M
Net Calls Change
-$8.56M

Top Buyers

1
DM
Deerfield Management
New York
+$82.1M
2
O
OrbiMed
New York
+$20.9M
3
TECP
Trails Edge Capital Partners
Georgia
+$15.2M
4
Citadel Advisors
Citadel Advisors
Florida
+$9.71M
5
UBS Group
UBS Group
Switzerland
+$9.5M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$62.9M
2
EAM
Eventide Asset Management
Massachusetts
-$26M
3
Goldman Sachs
Goldman Sachs
New York
-$15.2M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$14.2M
5
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$13.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$193M +$335K +15,424 +0.2%
KCM
2
Kynam Capital Management
New Jersey
$188M – – –
Goldman Sachs
3
Goldman Sachs
New York
$117M -$15.2M -698,588 -12%
State Street
4
State Street
Massachusetts
$103M -$3.62M -166,476 -4%
Bank of America
5
Bank of America
North Carolina
$99.3M -$10M -460,910 -10%
VCM
6
Vanguard Capital Management
Pennsylvania
$89.3M +$83.1M +3,822,579 New
DM
7
Deerfield Management
New York
$88.3M +$82.1M +3,779,900 New
EP
8
Eversept Partners
New York
$67.4M -$9.32M -428,786 -13%
KCM
9
Kingdon Capital Management
New York
$58.4M +$3.26M +150,000 +6%
HRCM
10
Hood River Capital Management
Florida
$55M +$820K +37,732 +2%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$50.4M +$1.44M +66,126 +3%
Franklin Resources
12
Franklin Resources
California
$50.2M -$5.9M -271,587 -11%
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$46.4M -$62.9M -2,896,506 -59%
EC
14
Elmind Capital
New York
$43.3M – – –
VPM
15
Vanguard Portfolio Management
Pennsylvania
$40.6M +$37.7M +1,737,141 New
BNP Paribas Asset Management
16
BNP Paribas Asset Management
France
$40.5M +$7.75M +356,860 +26%
SCM
17
Soleus Capital Management
Connecticut
$40.3M -$11.3M -520,202 -23%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$37.4M +$8.31M +382,287 +31%
Two Sigma Investments
19
Two Sigma Investments
New York
$36.9M +$9.4M +432,660 +38%
N
20
Nuveen
North Carolina
$34.9M +$253K +11,643 +0.8%
MB
21
MPM BioImpact
Massachusetts
$31.3M +$65.9K +3,031 +0.2%
ACM
22
Aisling Capital Management
New York
$30.8M – – –
WP
23
Woodline Partners
California
$29.2M +$2K +92 +0%
SC
24
Stempoint Capital
New York
$28.4M -$2.69M -123,636 -9%
UBS Group
25
UBS Group
Switzerland
$26.9M +$9.5M +437,443 +61%
1
2 3 4 5

SNDX Hedge Fund Activity: Q1 2026 in Review

246 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2026, worth a combined $2.32B — up 11% from $2.1B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new SNDX positions and 25 closed out — a net gain of 20 holders — while 99 added to existing stakes and 68 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $82.1M. The largest seller was Point72 Asset Management, cutting an estimated $62.9M.

  • 246 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2026, up from 229 in Q4 2025.
  • Funds reported $2.32B of Syndax Pharmaceuticals stock for Q1 2026, up 11% quarter-over-quarter.
  • 45 funds opened new Syndax Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +20 holders.
  • The largest Syndax Pharmaceuticals buyer in Q1 2026 was Deerfield Management, an estimated $82.1M added.
  • The largest Syndax Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $62.9M sold.

Based on aggregated 13F filings for Q1 2026.